CJC-1295 + Ipamorelin + BPC-157 + TB-500
Educational overview. This protocol is not FDA-approved and represents a research-based approach to supporting GH/IGF-axis signaling and muscle tissue. Consultation with a qualified medical provider is required before pursuing any therapy.
The Muscle Performance Protocol centers on two mechanisms: activation of the growth hormone and IGF-1 axis through two distinct pituitary pathways, and support of muscle and connective tissue repair. The layered approach — combining GHRH and ghrelin receptor signaling with peptides proposed to support tissue remodeling — reflects the hypothesis that GH/IGF-1 elevation alone is insufficient without concurrent support for the tissue that is supposed to respond to it.
CJC-1295 no DAC is an analogue of growth hormone-releasing hormone. It acts on GHRH receptors to increase the amplitude of endogenous growth hormone pulses. Without the drug affinity complex (DAC) binding, this form has a shorter half-life and requires more frequent dosing than the DAC version. Pharmacokinetic studies show elevation of GH and IGF-1 with dosing intervals typically requiring more frequent administration.
Ipamorelin is a ghrelin receptor agonist that triggers the initiation of GH pulses. Because it works through a different receptor pathway than CJC-1295, co-administration theoretically produces greater pulse amplitude and frequency than either alone. This is supported in preclinical models; human combination studies do not exist in the published literature.
BPC-157 is proposed to support tissue healing, with research examining effects on tendon, muscle, and ligament repair. Mechanisms proposed include effects on blood vessel formation, growth factor signaling, and neural function. The research base is primarily animal and in vitro; human evidence is limited.
TB-500 is a synthetic peptide studied for its effects on actin, a structural protein central to muscle and connective tissue function. Research has examined its potential role in muscle regeneration, wound healing, and inflammation modulation. Like BPC-157, the human evidence base is small.
GH and IGF-1 are anabolic signals that favor muscle growth and recovery. However, those signals require responsive tissue — muscle, tendon, and ligament that are capable of responding. BPC-157 and TB-500 are included on the hypothesis that supporting tissue repair capacity enhances the practical effect of elevated GH/IGF-1.
This is mechanistically coherent but untested as a combination. Individual compounds have research; the specific pairing does not.
The GH axis compounds (CJC-1295 and ipamorelin) have been pharmacologically characterized in humans. Studies show they do elevate GH and IGF-1 reliably.
The tissue-support compounds have a weaker evidence base. Animal studies and small human trials suggest mechanistic plausibility. Direct clinical outcomes in humans — strength, muscle mass, tissue integrity — have been examined minimally.
The critical distinction: showing that a compound raises a biomarker or shows in-vitro activity is not the same as showing it produces the clinical outcome claimed. Many compounds do the first reliably and the second not at all.
Growth hormone and IGF-1 are anabolic signals, but they do not build muscle in the absence of mechanical loading. Muscle adapts to load, and GH/IGF-1 can enhance that adaptation. The protocol without adequate resistance training is incomplete.
This protocol is not FDA-approved. Individual responses vary widely. Regulatory status is subject to change. Training and nutrition are foundational. Consult a qualified medical provider before pursuing any therapy.
